PMC:7408073 / 93114-93515 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T501","span":{"begin":136,"end":142},"obj":"Body_part"},{"id":"T502","span":{"begin":329,"end":335},"obj":"Body_part"}],"attributes":[{"id":"A501","pred":"fma_id","subj":"T501","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A502","pred":"fma_id","subj":"T502","obj":"http://purl.org/sig/ont/fma/fma62970"}],"text":"In normal healthy subjects, it was reproducibly below the limit of quantification [179,180], differently, both in ex vivo treatments of plasma samples with human rACE2 [115,181] and in ARDS patients, it was markedly increased (Ang (1–9) ranged between 100–3080 pg/mL) [92], suggesting both that the dominating activity of ACE in plasma of healthy subjects is overcome by that of ACE2 in ARDS patients."}

{"project":"LitCovid-PubTator","denotations":[{"id":"3233","span":{"begin":162,"end":167},"obj":"Gene"},{"id":"3234","span":{"begin":322,"end":325},"obj":"Gene"},{"id":"3235","span":{"begin":379,"end":383},"obj":"Gene"},{"id":"3263","span":{"begin":227,"end":235},"obj":"Gene"},{"id":"3285","span":{"begin":156,"end":161},"obj":"Species"},{"id":"3286","span":{"begin":190,"end":198},"obj":"Species"},{"id":"3287","span":{"begin":392,"end":400},"obj":"Species"},{"id":"3319","span":{"begin":185,"end":189},"obj":"Disease"},{"id":"3320","span":{"begin":387,"end":391},"obj":"Disease"}],"attributes":[{"id":"A3233","pred":"tao:has_database_id","subj":"3233","obj":"Gene:302668"},{"id":"A3234","pred":"tao:has_database_id","subj":"3234","obj":"Gene:59272"},{"id":"A3235","pred":"tao:has_database_id","subj":"3235","obj":"Gene:59272"},{"id":"A3263","pred":"tao:has_database_id","subj":"3263","obj":"Gene:284"},{"id":"A3285","pred":"tao:has_database_id","subj":"3285","obj":"Tax:9606"},{"id":"A3286","pred":"tao:has_database_id","subj":"3286","obj":"Tax:9606"},{"id":"A3287","pred":"tao:has_database_id","subj":"3287","obj":"Tax:9606"},{"id":"A3319","pred":"tao:has_database_id","subj":"3319","obj":"MESH:D012128"},{"id":"A3320","pred":"tao:has_database_id","subj":"3320","obj":"MESH:D012128"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"In normal healthy subjects, it was reproducibly below the limit of quantification [179,180], differently, both in ex vivo treatments of plasma samples with human rACE2 [115,181] and in ARDS patients, it was markedly increased (Ang (1–9) ranged between 100–3080 pg/mL) [92], suggesting both that the dominating activity of ACE in plasma of healthy subjects is overcome by that of ACE2 in ARDS patients."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T530","span":{"begin":185,"end":189},"obj":"Disease"},{"id":"T531","span":{"begin":387,"end":391},"obj":"Disease"}],"attributes":[{"id":"A530","pred":"mondo_id","subj":"T530","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A531","pred":"mondo_id","subj":"T531","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"}],"text":"In normal healthy subjects, it was reproducibly below the limit of quantification [179,180], differently, both in ex vivo treatments of plasma samples with human rACE2 [115,181] and in ARDS patients, it was markedly increased (Ang (1–9) ranged between 100–3080 pg/mL) [92], suggesting both that the dominating activity of ACE in plasma of healthy subjects is overcome by that of ACE2 in ARDS patients."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1131","span":{"begin":136,"end":142},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T1132","span":{"begin":156,"end":161},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T1133","span":{"begin":261,"end":263},"obj":"http://purl.obolibrary.org/obo/CLO_0008426"},{"id":"T1134","span":{"begin":310,"end":318},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T1135","span":{"begin":329,"end":335},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"}],"text":"In normal healthy subjects, it was reproducibly below the limit of quantification [179,180], differently, both in ex vivo treatments of plasma samples with human rACE2 [115,181] and in ARDS patients, it was markedly increased (Ang (1–9) ranged between 100–3080 pg/mL) [92], suggesting both that the dominating activity of ACE in plasma of healthy subjects is overcome by that of ACE2 in ARDS patients."}

{"project":"LitCovid-sentences","denotations":[{"id":"T451","span":{"begin":0,"end":401},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In normal healthy subjects, it was reproducibly below the limit of quantification [179,180], differently, both in ex vivo treatments of plasma samples with human rACE2 [115,181] and in ARDS patients, it was markedly increased (Ang (1–9) ranged between 100–3080 pg/mL) [92], suggesting both that the dominating activity of ACE in plasma of healthy subjects is overcome by that of ACE2 in ARDS patients."}

{"project":"2_test","denotations":[{"id":"32708755-25107336-20679002","span":{"begin":83,"end":86},"obj":"25107336"},{"id":"32708755-2170511-20679003","span":{"begin":87,"end":90},"obj":"2170511"},{"id":"32708755-22777933-20679004","span":{"begin":169,"end":172},"obj":"22777933"},{"id":"32708755-22518284-20679005","span":{"begin":173,"end":176},"obj":"22518284"},{"id":"32708755-30845246-20679006","span":{"begin":269,"end":271},"obj":"30845246"}],"text":"In normal healthy subjects, it was reproducibly below the limit of quantification [179,180], differently, both in ex vivo treatments of plasma samples with human rACE2 [115,181] and in ARDS patients, it was markedly increased (Ang (1–9) ranged between 100–3080 pg/mL) [92], suggesting both that the dominating activity of ACE in plasma of healthy subjects is overcome by that of ACE2 in ARDS patients."}